CD
Therapeutic Areas
Actinium Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ATNM-400 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Preclinical |
| Actimab-A | Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) | Phase 2/3 |
| Iomab-B | Relapsed/Refractory AML (Conditioning for BMT) | Phase 3 |
| Iomab-ACT | Conditioning for Cell & Gene Therapies | Preclinical |
| HER3-Targeting Radiotherapy | Solid Tumors | Preclinical |
Leadership Team at Actinium Pharmaceuticals
SS
Sandesh Seth
Chief Executive Officer and Chairman of the Board
AK
Adeela Kamal
Executive Vice President, Head of Research and Development
JG
Julie Gibson
Vice President, Portfolio and Clinical Operations
PD
Paul Diamond
Vice President, Legal and Intellectual Property Counsel
RC
Ryan Chu
Vice President, Finance and Investor Relations
AS
Ajit Shetty
Director